Surbhi Sarna - 03 Jan 2023 Form 4 Insider Report for BIORA THERAPEUTICS, INC. (BIORQ)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
05 Jan 2023, 15:05:34 UTC
Prior SEC filing
05 Oct 2022
Next SEC filing
22 Feb 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Will Pridgen, Attorney-in-Fact for Surbhi Sarna

Key filing fact

Surbhi Sarna filed Form 4 for BIORA THERAPEUTICS, INC. (BIORQ) on 05 Jan 2023.

Key facts

  • This page summarizes Surbhi Sarna's Form 4 filing for BIORA THERAPEUTICS, INC. (BIORQ).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 05 Jan 2023, 15:05.

Change

  • Previous filing in this sequence was filed on 05 Oct 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BIOR transaction

Series X Preferred Stock

Disposed to Issuer

Transaction value
Shares
-8
Change %
-100%
Price
Shares after
0
Date
03 Jan 2023
Ownership
Direct
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On November 10, 2022, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series X Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on November 21, 2022, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on November 21, 2022. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company.

Footnote F2

On January 3, 2023, in connection with the Company's reverse stock split for the common stock, the shares of Preferred Stock were redeemed automatically in accordance with the certificate of designation of the Preferred Stock. Each share of Preferred Stock was redeemed in consideration for the right to receive an amount equal to $0.001 in cash (rounded to the nearest cent) for each whole share of Preferred Stock.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .